Acme Bioscience

Acme Bioscience is a specialized chemistry CRO that was acquired by the publicly traded Frontage Holdings Corporation in 2020, integrating it into a larger global CRO platform. The company's core value proposition lies in its deep expertise in synthetic and medicinal chemistry, especially within antiviral and antibacterial research, serving as an alliance partner for pharma and biotech clients. As part of Frontage, it now leverages a 'Two Countries, One System' model to offer integrated drug development services across the US and China. Its business is entirely service-based, generating revenue through contracted research work rather than developing its own therapeutic assets.

Expertise in complex organic synthesis and medicinal chemistry, with specialized knowledge in antiviral/antibacterial research, nucleotides, nucleosides, prodrugs, heterocycles, and boron-containing compounds. Operates as a service-based chemistry CRO.

Operates in the highly competitive global CRO market, competing with large, full-service CROs (e.g., LabCorp, IQVIA), specialized chemistry providers, and low-cost regional players. Differentiation relies on deep technical expertise in complex chemistry and its integrated offering through Frontage's cross-border platform.